Onco Wiki / Bandera roja

HHV-8 (herpesvirus asociado a los sarcomas de Kaposi, KSHV) seropositividad en una inmunocompromisa...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-CHRONIC-HHV8-MALIGNANCY-PREVENTION
TipoSeñal de alerta
Situaciónreviewed 2026-05-18 | pending_clinical_signoff
EnfermedadesDIS-KAPOSI
FuentesSRC-IARC-MONO-100B-2012 SRC-NIH-AIDS-2024

Origen de la bandera roja

DefiniciónHHV-8 (Kaposi sarcoma-associated herpesvirus, KSHV) seropositivity in an immunocompromised host (HIV+, solid-organ-transplant recipient on chronic immunosuppression, or other persistent T-cell-immunity deficit) without a current Kaposi sarcoma, multicentric Castleman disease (MCD), or primary effusion lymphoma (PEL) diagnosis. IARC Group 1 carcinogen (HHV-8) — established etiological driver of all three lymphoproliferative outcomes. No curative antiviral exists; the prevention pathway is restoration / optimization of cellular immunity (ART initiation for HIV+; minimization of immunosuppression where transplant-graft-safe) plus mucocutaneous + oral + GI awareness and lymph-node surveillance. Prevention-persona RedFlag (§20 ratification 2026-05-18).
Dirección clínicainvestigación
Categoríaotros

Lógica de activación

{
  "any_of": [
    {
      "finding": "hhv8_serology",
      "value": "positive"
    },
    {
      "finding": "kshv_serology",
      "value": "positive"
    },
    {
      "finding": "hhv8_status_in_immunocompromised",
      "value": "positive"
    }
  ],
  "type": "lab_value"
}

Notas

Prevention-persona RedFlag for HHV-8-driven malignancy prevention. Fires on HHV-8 seropositivity in HIV+, transplant, or other immunocompromised host without confirmed Kaposi sarcoma / MCD / PEL. Engine routes to PreventionPlan recommending immune restoration (ART for HIV+; transplant-immunosuppression rebalance) + mucocutaneous + oral + GI / lymph-node surveillance. STUB pending Co-Lead review. Cancer scope: anchored to DIS-KAPOSI. MCD and PEL are HHV-8-driven but not yet authored as distinct Disease entities — covered via the prose surveillance rationale in the indication for now. Distinct from RF-CHRONIC-HIV-MALIGNANCY-PREVENTION (existing) — that is HIV-as-RF; this is HHV-8-positivity-as-RF (the co-factor that turns HIV-related immunocompromise into Kaposi risk specifically).

Utilizado por

Indicación

Señal de alerta